↓ Skip to main content

Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

Overview of attention for article published in BMC Medicine, May 2022
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
20 Mendeley